Last reviewed · How we verify
NaCl 3%
Hypertonic saline (3% NaCl) increases serum osmolality to draw fluid from intracellular and interstitial spaces into the intravascular compartment, reducing cerebral edema and intracranial pressure.
Hypertonic saline (3% NaCl) increases serum osmolality to draw fluid from intracellular and interstitial spaces into the intravascular compartment, reducing cerebral edema and intracranial pressure. Used for Cerebral edema and elevated intracranial pressure, Traumatic brain injury, Acute stroke management.
At a glance
| Generic name | NaCl 3% |
|---|---|
| Also known as | Mucoclear 3% |
| Sponsor | Raphaelle Jaquet-Pilloud |
| Drug class | Osmotic agent / Hypertonic saline |
| Modality | Small molecule |
| Therapeutic area | Neurology / Critical Care |
| Phase | Phase 3 |
Mechanism of action
3% sodium chloride solution is a hypertonic agent that creates an osmotic gradient across cell membranes and the blood-brain barrier. This osmotic effect mobilizes fluid from edematous tissues into the vascular space, thereby reducing intracranial pressure and cerebral edema. It is commonly used in acute neurological emergencies to manage elevated intracranial pressure.
Approved indications
- Cerebral edema and elevated intracranial pressure
- Traumatic brain injury
- Acute stroke management
Common side effects
- Hypernatremia
- Hyperchloremia
- Phlebitis (at infusion site)
- Rebound intracranial pressure elevation
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Effects of Bronchial Segmental Endotoxin Instillation in Humans (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NaCl 3% CI brief — competitive landscape report
- NaCl 3% updates RSS · CI watch RSS
- Raphaelle Jaquet-Pilloud portfolio CI